Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.51 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730613 | 0.85 | BRD4 (0.54) | BRD4HSPB1 | |
| SCHEMBL29548873 | 0.77 | BRD4 (0.58) | BRD4CYP17A1 | |
| SCHEMBL28720346 | 0.77 | BRD4 (0.58) | BRD4CYP17A1 | |
| SCHEMBL29548631 | 0.76 | BRD4 (0.56) | BRD4 | |
| SCHEMBL3210448 | 0.73 | BRD4 (0.44) | BRD4CYP17A1 | |
| SCHEMBL16651036 | 0.71 | BRD4 (0.48) | BRD4 | |
| SCHEMBL3198482 | 0.71 | CYP17A1 (0.48) | BRD4CYP17A1 | |
| SCHEMBL16868381 | 0.70 | BRD4 (0.58) | BRD4 | |
| SCHEMBL16660689 | 0.70 | BRD4 (0.59) | BRD4 | |
| SCHEMBL16658392 | 0.70 | BRD4 (0.55) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | BRD4 3241/4885HSPB1 3201/4885PTPN1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.